Connor Clark & Lunn Investment Management Ltd. Makes New $758,000 Investment in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 69,548 shares of the biopharmaceutical company’s stock, valued at approximately $758,000. Connor Clark & Lunn Investment Management Ltd. owned 0.12% of Vanda Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in VNDA. Envestnet Asset Management Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter worth $110,000. Assetmark Inc. grew its position in Vanda Pharmaceuticals by 26.4% in the 2nd quarter. Assetmark Inc. now owns 73,767 shares of the biopharmaceutical company’s stock valued at $804,000 after acquiring an additional 15,400 shares in the last quarter. Victory Capital Management Inc. increased its stake in Vanda Pharmaceuticals by 5.9% during the second quarter. Victory Capital Management Inc. now owns 273,915 shares of the biopharmaceutical company’s stock worth $2,986,000 after purchasing an additional 15,334 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Vanda Pharmaceuticals by 89.9% during the second quarter. Assenagon Asset Management S.A. now owns 2,526,480 shares of the biopharmaceutical company’s stock worth $27,539,000 after purchasing an additional 1,195,768 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $187,000. 99.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 3rd.

Insiders Place Their Bets

In other news, CMO Joakim Wijkstrom sold 3,605 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $10.27, for a total value of $37,023.35. Following the sale, the chief marketing officer now directly owns 96,673 shares in the company, valued at approximately $992,831.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $10.42 on Thursday. The business has a 50-day simple moving average of $10.13 and a 200-day simple moving average of $10.31. Vanda Pharmaceuticals Inc. has a one year low of $9.24 and a one year high of $18.40. The company has a market cap of $589.67 million, a PE ratio of 86.84 and a beta of 0.50.

Vanda Pharmaceuticals Company Profile

(Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Articles

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.